I like Paysign, Inc. (PAYS)

I found this on a scanner AFTER the huge move on earnings
But I think it will still be a great investment. This one is not as speculative as others I've mentioned. It's more of a fundamental investment.

I was looking for small market cap, profitability, growth, but also trading at an attractive valuation. I'm very happy to have found Paysign.
Here's some AI driven content that I've steered:

Paysign provides specialized fintech solutions for pharmaceutical copay assistance and plasma donor compensation through its proprietary payment processing platform.

As of late March 2026, Paysign has reached a milestone where its high-margin pharmaceutical payment services are beginning to equal its legacy plasma business in total revenue. This shift follows a year of expansion in which the company added 55 new patient affordability programs and completed a strategic acquisition to deepen its integration into plasma collection centers. With a debt-free balance sheet and a focus on technology that reduces costs for pharmaceutical manufacturers, the company is now prioritizing profitability through operating leverage.

1. Hyper-Growth Pharma Pivot: Paysign is transforming into a high-margin pharmaceutical fintech, with pharma revenue growing 168% in 2025.
2. Powerful Operating Leverage: Management expects to nearly double net income to a 14.5 million dollar midpoint in 2026 on 32% revenue growth.
3. Attractive Valuation: Trading at a 0.44 PEG ratio and roughly 22x forward earnings, the stock remains undervalued relative to its 90% income growth.
4. Clean Balance Sheet: The company is entirely debt-free with 21.1 million dollars in unrestricted cash, allowing it to self-fund all current expansion.
5. Bullish Analyst Outlook: Wall Street maintains a 9.25 dollar consensus price target, implying roughly 80% upside from current trading levels.





A bit on Dynamic Business Rules:

The Dynamic Business Rules (DBR) technology effectively acts as a referee in a high-stakes financial game. Here is how the power dynamics shift when Paysign is in the middle:

The Winners

Drug Makers (Pharma): They are the biggest winners. They stop "bleeding" money to insurance middlemen. In 2025 alone, they kept $325 million that would have otherwise been siphoned away. This allows them to maintain their assistance budgets and help more people.

Patients: They win through stability. Instead of their copay assistance "running out" in April because an insurer drained the fund, Paysign’s metering ensures the money lasts all 12 months. This prevents "cost shock" and helps patients stay on their life-saving meds.

Paysign (PAYS): By proving they can save a Top-10 pharma company millions of dollars on day one, Paysign becomes "un-fireable." This tech is their primary "moat" that is currently driving their 90% income growth.

The Losers

Insurance Companies & PBMs: They are the clear losers. For years, they used "Maximizer" and "Accumulator" programs to quietly pocket manufacturer assistance funds for themselves. Paysign’s 97% accuracy in spotting these tricks effectively shuts down a major, hidden revenue stream for insurers.